NYSE:JBLElectronic
Jabil (JBL) Gets An FDA Warning Letter, Is The Stock Still 26% Undervalued?
Jabil (JBL) is under fresh regulatory scrutiny after the FDA issued a detailed warning letter citing significant Current Good Manufacturing Practice violations at its Pharmaceutics International sterile injectables facility.
At a share price of US$318.08, Jabil has seen a sharp 5.05% 1 day share price return and a 2.42% 7 day share price return, even though the 30 day share price return is down 13.13% and the 90 day share price return is down 17.34%. Total shareholder return of 32.32% year to...